REGULATORY
    Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
    By Takashi Ebisawa October 5, 2026
    Japan has limited room to respond to the US most-favored-nation (MFN) policy through its drug pricing system, a senior Ministry of Finance (MOF) official told Jiho, as policymakers gear up to flesh out the FY2027…

    LATEST

    Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
    October 5, 2026
    Daiichi Sankyo and AstraZeneca have struck a deal with Summit Therapeutics for the global development of a combination therapy pairing their TROP2-directed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) with the US firm’s PD-1/VEGF bispecific…
    Taiho, Cullinan Start US Filing for Zipalertinib-Chemo Combo
    October 5, 2026
    Taiho Pharmaceutical and development partner Cullinan Therapeutics have begun submitting a new drug application to the US FDA for zipalertinib in combination with a platinum-based chemotherapy under the agency’s Real-Time Oncology Review (RTOR) program.The filing…
    Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
    October 5, 2026
    Japan needs to strengthen its diagnostic framework for Stargardt disease, including access to genetic testing, an expert said on October 2, with what could be the country’s first drug for the rare inherited retinal disorder…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COLUMN

    Outside the Bubble: Lunch with Pharma Delegates
    By Philip Carrigan

    The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…

    COMMENTARY

    Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
    By Shinya Sato

    The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA